Moody's upgrades Biogen (BIIB) from Baa3 to Baa2; outlook Stable
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Join SI Premium – FREE
Moody's upgrades Biogen (Nasdaq: BIIB) from Baa3 to Baa2; outlook Stable
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
- GitLab Inc (GTLB) PT Raised to $54 at BofA Securities
Create E-mail Alert Related Categories
Credit RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
